• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Avadel Pharmaceuticals plc

    2/13/24 9:40:50 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVDL alert in real time by email
    SC 13G 1 polar-avdl123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    AVADEL PHARMACEUTICALS PLC

    (Name of Issuer)

     

    American Depository Shares, each representing on Ordinary Share, nominal value $0.01 per share

    (Title of Class of Securities)

     

    05337M104

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  05337M104
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital Holdings Plc
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    6,751,782
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    6,751,782
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,751,782
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.51%
    12
    TYPE OF REPORTING PERSON
     
    HC

     


     

    CUSIP No.  05337M104
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    6,751,782
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    6,751,782
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,751,782
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.51%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No. 05337M104
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    AVADEL PHARMACEUTICALS PLC

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    10 Earlsfort Terrace

    Dublin 2, Ireland

    D02 T380

    Item 2.(a) Name of Person Filing:

     

    Polar Capital Holdings Plc

    Polar Capital LLP

     

    Item 2.(b,) Address of Principal Business Office:

     

    16 Palace Street

    London, SW1E 5JD

     

    Item 2.(c) Citizenship:

     

    United Kingdom

      

    Item 2.(d) Title of Class of Securities

    American Depository Shares, each representing on Ordinary Share, nominal value $0.01 per share (the “Shares”)

     

    Item 2.(e) CUSIP No.:

    05337M104

     

    CUSIP No.  05337M104
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 05337M104
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1:

    Polar Capital Holdings Plc

    (a) Amount beneficially owned: 6,751,782

    (b) Percent of class: 7.51%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 6,751,782

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 6,751,782

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    Polar Capital LLP

    (a) Amount beneficially owned: 6,751,782

    (b) Percent of class: 7.51%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 6,751,782

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 6,751,782

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    * Based on 89,805,653 shares outstanding as reported in the Issuer's Form 10-Q on November 8, 2023.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Information for each Subsidiary is incorporated on the respective cover pages.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 05337M104
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           

     

     
    CUSIP No. 05337M104
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 13, 2022

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           
    Get the next $AVDL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVDL

    DatePrice TargetRatingAnalyst
    2/11/2025$12.00Buy
    Deutsche Bank
    6/12/2024$27.00Buy
    Rodman & Renshaw
    3/5/2024$27.00 → $29.00Outperform
    Oppenheimer
    3/5/2024$21.00 → $25.00Buy
    H.C. Wainwright
    3/5/2024$20.00 → $22.00Buy
    Needham
    2/6/2024$21.00Buy
    UBS
    11/30/2022$6.50 → $11.00Hold → Buy
    Jefferies
    8/10/2022$6.00 → $8.00Buy → Hold
    Jefferies
    More analyst ratings

    $AVDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on Avadel Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      2/11/25 7:00:38 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Avadel Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00

      6/12/24 7:06:25 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Avadel Pharmaceuticals with a new price target

      Oppenheimer reiterated coverage of Avadel Pharmaceuticals with a rating of Outperform and set a new price target of $29.00 from $27.00 previously

      3/5/24 7:51:39 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the se

      5/8/25 4:05:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

      -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in

      5/7/25 7:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

      - With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") has ruled in favor of Avadel, overturning important parts of the injunction imposed by the U.S. District Court for the District of Delaware (the "Delaware Court") rega

      5/6/25 12:30:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Financials

    Live finance-specific insights

    See more
    • Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

      -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in

      5/7/25 7:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

      DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are

      4/30/25 8:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

      DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here a

      2/24/25 4:05:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

      SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

      11/14/24 6:10:30 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

      SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

      11/13/24 5:58:54 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

      SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

      11/13/24 5:00:57 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gen. Counsel & Corp. Secretary Seurer Jerad G. was granted 14,700 units of Ordinary Shares, increasing direct ownership by 167% to 23,495 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      3/7/25 4:09:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Mchugh Thomas S was granted 12,600 units of Ordinary Shares, increasing direct ownership by 14% to 100,400 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      3/7/25 4:07:45 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Divis Gregory J was granted 52,000 units of Ordinary Shares, increasing direct ownership by 33% to 211,100 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      3/7/25 4:06:44 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Leadership Updates

    Live Leadership Updates

    See more
    • Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

      DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build

      2/24/25 8:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

      DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin

      1/22/25 8:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals to Join Russell 3000® Index

      DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit

      6/27/24 4:05:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avadel Pharmaceuticals plc

      10-Q - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

      5/7/25 9:20:30 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

      5/7/25 7:07:12 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

      5/6/25 2:59:18 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      1/22/25 4:13:34 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      1/14/25 4:24:12 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ende Eric J bought $235,218 worth of Ordinary Shares (30,000 units at $7.84), increasing direct ownership by 17% to 208,900 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      1/14/25 4:22:57 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care